Features | Partner Sites | Information | LinkXpress
Sign In
TERARECON, INC.
SCHILLER AG
AMPRONIX

MRI T1 Mapping Technique Diagnoses Genetic Disorder That Attacks the Heart, Brain, and Nerves

By Medimaging International staff writers
Posted on 16 Oct 2013
A genetic disorder that attacks multiple organs and typically causes fatal heart complications can be detected using a new magnetic resonance imaging (MRI) technique. This new diagnostic application has resulted in updated clinical guidelines for the diagnosis and treatment of Fabry disease in Canada.

The University of Alberta’s (Edmonton, AB, Canada) Faculty of Medicine & Dentistry researchers Drs. Gavin Oudit and Richard Thompson worked with Faculty colleagues Drs. Kelvin Chow and Alicia Chan on the discovery, as well as Dr. Aneal Khan from the University of Calgary (Alberta, Canada). The findings were published online before August 6, 2013, in the journal, Circulation-Cardiovascular Imaging, and involved 31 Alberta patients who have the disease.

Dr. Thompson and trainee Dr. Chow developed the MRI technique known as T1 mapping, which can identify heart damage and changes at early stages, earlier than regular MRI scans or ultrasound. When this type of MRI technology is used on patients with Fabry disease, the scans can detect both the disease and the degree of damage to the heart. The T1 mapping technology developed by the group can be easily programmed onto MRI scans worldwide.

“This test can uniquely identify Fabry disease by detecting microscopic changes in the heart muscle structure that are not visible on regular images,” said Dr. Thompson, who works in the department of biomedical engineering. “Fabry disease can look like other diseases if you only look at the whole heart structure or function, but this T1 mapping test, that can detect the tiniest changes in the heart, could identify all the patients with Fabry disease. It is very likely that this technique will become a key part in clinical examination of patients with Fabry disease. This finding will advance the clinical care of these patients around the world. The implications will be widespread. Heart disease is the number one cause of death for patients with Fabry disease. The earlier the disease can be pinpointed, the sooner treatment can start. The treatment for the disease halts the condition and prevents serious damage to the heart.”

Fabry disease is a genetic metabolic disorder that destroys the enzyme involved in fat metabolism. This enzyme dissolves fat so without it, those with the disease accumulate lethal fat deposits in their heart, kidneys, and brain. The condition affects 1 in 1,500 to 3,000 people, but was first believed to be a rare disease. Various countries now screen newborns for the condition that costs USD 200,000 yearly to treat through monthly infusions called enzyme replacement therapy. Symptoms of the disease include heart failure, blackouts, thickened walls of the heart, exercise intolerance, fluid accumulation in the legs, inability to lie down, strokes, tingling in the hands and feet, and changes in skin pigmentation.

The T1 mapping test can both detect the disease and evaluate damage to the heart. Dr. Oudit reported that this new MRI technique “is a wonderful story of collaboration--of patients, clinicians, scientists, and industry working together to find a new diagnostic tool.”

“As an organization, we are excited to be part of these developments through the research from the University of Alberta,” said Mauro Chies, acting vice-president of clinical supports for Alberta Health Services. “This is a significant advancement in the detection of disease in a noninvasive environment for our patients. We hope to be able to advance these sequences on our MRIs in the near future, and look for ways to use it to evaluate and detect other disease conditions.”

The project was done in collaboration with Siemens Canada, Ltd. and Siemens Healthcare USA, Inc. (Malvern, PA, USA).

Related Links:

University of Alberta
University of Calgary
Siemens Healthcare




SuperSonic Imagine
RADCAL
RTI ELECTRONICS AB

Channels

Radiography

view channel

Leading Cancer Center Among First in Europe to Treat Patients Using Robotic Patient-Positioning Radiotherapy Couch

A Viennese hospital has become one of the first oncology departments in Europe to introduce clinical treatments using a robotic radiotherapy patient-positioning couch. Kaiser-Franz-Josef Hospital (KFJ; Vienna, Austria) has introduced this enhanced patient positioning device, which enables more flexibility during radiotherapy... Read more

Ultrasound

view channel
Image: Very high magnification micrograph of fibrolamellar hepatocellular carcinoma showing the characteristic laminated fibrosis between the tumor cells with a low N/C ratio. H&E stain (Photo courtesy of Wikimedia Commons).

Hepatocellular Carcinoma Screening Linked with Curative Treatment and Longer Survival in Cirrhosis Patients

Investigators discovered that patients with cirrhosis who underwent surveillance (using liver ultrasound with or without measurement of serum alpha fetoprotein) for hepatocellular carcinoma (HCC) had cancers... Read more

Nuclear medicine

view channel
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Enterprise Image-Viewing System Receives FDA Clearance for Mobile Diagnosis on All Modalities

An enterprise image-viewing system is now cleared in the United States for diagnosis on mobile devices, for all imaging modalities (except mammography). Calgary Scientific, Inc. (Calgary, AB, USA) recently reported their latest Class II clearance from the US Food and Drug Administration (FDA). Calgary Scientific worked... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.